Evidence map›Paper›PMID 28935992›Full record

ArticleLeukemia2018

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

S K Balasubramanian, M Aly, Y Nagata, T Bat, B P Przychodzen, C M Hirsch, V Adema, V Visconte, T Kuzmanovic, T Radivoyevitch and 4 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  3. Frontiers in oncology · 2022
    Article
  4. Review
  5. Alterations toCancer research · 2021
    Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

S K BalasubramanianDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
M AlyDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
Y NagataDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
T BatDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
B P PrzychodzenDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
C M HirschDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
V AdemaDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
V VisconteDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
T KuzmanovicDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
T RadivoyevitchDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
A NazhaDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
S MukherjeeDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
M A SekeresDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
J P MaciejewskiDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
Cleveland Clinic · US

Funding

Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7M
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1M
Investigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9M
The Role of Somatic Mutations in Aplastic AnemiaR01HL128425 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2015 to 2016
$793k
NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL128425NHLBI NIH HHS R35 HL135795
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansLeukemia, Myeloid, AcuteMaleMutationPrognosisDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, human

Identifiers

PMID28935992
PMCPMC8404553
OpenAlexW2757402478

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.